News for Sorrento Therapeutics Inc Stock (SRNE)

Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern

GlobeNewsWire • 08/19/21

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives

GlobeNewsWire • 08/19/21

Why Dynavax, Novavax, and Sorrento Soared This Week

The Motley Fool • 08/13/21

Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Accesswire • 08/12/21

Dyadic Stock Jumps On Development Pact With Sorrento For Diagnostics & Therapies For Coronaviruses

Benzinga • 08/11/21

7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught

InvestorPlace • 08/11/21

Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic's Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

GlobeNewsWire • 08/11/21

Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program

GlobeNewsWire • 08/09/21

Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model

GlobeNewsWire • 08/04/21

Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS-C

GlobeNewsWire • 08/03/21

Sorrento Therapeutics To Start Testing DAR-T Cell Therapy In Multiple Myeloma Patients

Benzinga • 08/02/21

Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma

GlobeNewsWire • 08/02/21

Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

Zacks Investment Research • 07/28/21

Will Sorrento Therapeutics (SRNE) Report Negative Q2 Earnings? What You Should Know

Zacks Investment Research • 07/27/21

7 Meme Stocks That You Shouldn't Touch With a 10-Foot Pole

InvestorPlace • 07/27/21

Sorrento Therapeutics: Lots Of News Can Bring The Stock Up

Seeking Alpha • 07/27/21

Lee's Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

GlobeNewsWire • 07/23/21

Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors

GlobeNewsWire • 07/21/21

Sorrento Starts Patient Dosing In Mid-Stage COVID-19 Trial With Nasal Neutralizing Antibody

Benzinga • 07/21/21

Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom

GlobeNewsWire • 07/21/21

Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento's Portfolio of COVID-19 Products in Mexico and Parts of Latin America

GlobeNewsWire • 07/20/21

Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management

GlobeNewsWire • 07/20/21

Why Sorrento Therapeutics Is Down 9% This Week

The Motley Fool • 07/08/21

Why Sorrento Therapeutics Stock Gained 29% Last Month

The Motley Fool • 07/08/21

Sorrento To Start Testing Non-Opioid Candidate In Osteoarthritis-Related Knee Pain

Benzinga • 07/07/21